Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Hightower

Internal Medicine Cushing, OK Doctor of Osteopathy

NPI 1861425878 CMS profile 175624

1025 E 2Nd St, Cushing, OK 74023

Open in the dashboard

General payments

$8,166

502 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Hightower of Cushing, OK is reported in the CMS Open Payments database as having received $8,166 across 502 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,297 76
2024 General $1,443 77
2023 General $1,468 92
2022 General $1,810 115
2021 General $677 44
2020 General $552 37
2019 General $919 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Hightower
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Robert Hightower were reported at $1,297. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Robert Hightower Internal Medicine median Middle half National median
2019 $919 $159 $48–$570 $163
2020 $552 $119 $33–$402 $114
2021 $677 $135 $37–$521 $132
2022 $1,810 $141 $42–$496 $149
2023 $1,468 $149 $45–$519 $160
2024 $1,443 $154 $47–$537 $164
2025 $1,297 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,432 73 payments
  2. AbbVie, Inc. $1,016 78 payments
  3. GlaxoSmithKline, LLC. $831 59 payments
  4. Lilly USA, LLC $448 31 payments
  5. Pfizer Inc. $389 26 payments
  6. Novo Nordisk Inc $310 20 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $261 17 payments
  8. Janssen Pharmaceuticals, Inc $243 16 payments
  9. Sumitomo Pharma America, Inc. $221 11 payments
  10. Mylan Specialty L.P. $212 11 payments
  11. Other $2,804 160 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,166 502 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $737 32 payments
  2. TRELEGY ELLIPTA $699 46 payments
  3. BREZTRI $637 30 payments
  4. VRAYLAR $374 31 payments
  5. MOUNJARO $291 20 payments
  6. YUPELRI $283 14 payments
  7. GEMTESA $282 15 payments
  8. AIRSUPRA $264 10 payments
  9. UBRELVY $263 15 payments
  10. TRULICITY $243 17 payments
  11. Other $6,622 430 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 206 drugs

Part D claims

19,360

Median for Internal Medicine: 777

Drug cost

$1,082,026

Median for Internal Medicine: $73,373

Branded share of claims

24.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 134 $137,648
Eliquis Apixaban Brand 282 $134,631
Mounjaro Tirzepatide Brand 85 $101,101
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 63 $65,965
Jardiance Empagliflozin Brand 70 $58,070
Xarelto Rivaroxaban Brand 116 $57,980
Gemtesa Vibegron Brand 119 $39,830
Rexulti Brexpiprazole Brand 44 $35,127
Linzess Linaclotide Brand 42 $26,760
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 999 $26,524

The 10 drugs with the highest cost, of 206 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$251,579

Of which drugs: $15,428

Medicare patients

406

Average age 76

Services billed

43,506

227 women, 179 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Diabetes 34%
Depression 34%
COPD 32%
Ischemic heart disease 30%
Atrial fibrillation 23%
Heart failure 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 59 59 $4,827
Injection, methylprednisolone acetate, 1 mg J1010 Office 140 21,840 $2,210
Injection, methylprednisolone acetate, 80 mg J1040 Office 84 105 $589
Injection, ceftriaxone sodium, per 250 mg J0696 Office 136 940 $309
Injection, testosterone cypionate, 1 mg J1071 Office 18 13,901 $243
Injection, ketorolac tromethamine, per 15 mg J1885 Office 87 358 $182
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 62 177 $167
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 170 1,556 $128
Injection, furosemide, up to 20 mg J1940 Office 23 82 $32

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $89
  • Otsuka America Pharmaceutical, Inc. $76
$165 44 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $153
$153 24 —
GEMTESA
  • Sumitomo Pharma America, Inc. $147
$147 119 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $132
$132 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $97
$97 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

502 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record